Natural and Synthetic Agents Enhance Autophagy to Mitigate Doxorubicin Cardiotoxicity
Overview
Doxorubicin-induced cardiomyopathy affects nearly 30% of patients and is linked to impaired autophagy. This study demonstrates that natural agents trehalose and spermidine, along with the synthetic peptide Tat-Beclin 1 D11, enhance autophagic activity and improve cardiac function in a murine model of doxorubicin cardiotoxicity without compromising antitumor efficacy.
Background
Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent widely used against various cancers but is limited by dose-dependent cardiotoxicity leading to cardiomyopathy. Autophagy, a cellular degradation and recycling process, plays a critical role in maintaining cardiac homeostasis, and its impairment contributes to DOX-induced cardiac injury. Pharmacological activation of autophagy has emerged as a promising strategy to mitigate cardiac damage. Natural compounds such as trehalose and spermidine, both FDA-approved dietary supplements, and synthetic peptides like Tat-Beclin 1 D11 have shown potential as autophagy activators.
Data Highlights
Mice received cumulative DOX doses (15 mg/kg) and were treated with trehalose (2% in water plus 1 g/kg i.p.), spermidine (3 mM in water), or Tat-Beclin 1 D11 (15 mg/kg i.p. thrice weekly) for six weeks. Cardiac function was assessed by echocardiography measuring fractional shortening, ejection fraction, and global longitudinal strain. Tumor growth was monitored in a syngeneic breast cancer model to evaluate potential interference with DOX antitumor activity.
Key Findings
DOX administration induced significant cardiomyopathy characterized by impaired cardiac function and mitochondrial damage in mice.
Trehalose and spermidine treatments enhanced autophagic flux, reduced mitochondrial damage, and improved cardiac remodeling and function post-DOX exposure.
Tat-Beclin 1 D11, a synthetic autophagy activator, similarly improved cardiac outcomes by specifically targeting autophagy machinery.
None of the autophagy-enhancing agents interfered with the antitumor efficacy of DOX in the murine breast cancer model.
Both natural and synthetic autophagy activators represent promising cardioprotective strategies during DOX chemotherapy.
Clinical Implications
These findings support the potential use of autophagy-inducing agents such as trehalose and spermidine as adjunct therapies to prevent or mitigate DOX-induced cardiotoxicity in cancer patients. The preservation of DOX's antitumor activity alongside cardioprotection highlights the translational relevance of these agents. Clinicians should consider autophagy modulation as a therapeutic avenue to improve cardiovascular outcomes during anthracycline chemotherapy.
Conclusion
Pharmacological enhancement of autophagy via natural supplements or synthetic peptides effectively mitigates doxorubicin-induced cardiomyopathy without compromising anticancer efficacy, offering a promising strategy to improve cardiovascular health in cancer patients undergoing chemotherapy.
References
Article Source 2024 -- Natural and Synthetic Agents Enhance Autophagic Activity to Mitigate Doxorubicin-Induced Cardiomyopathy
